


Travel Centre

ticket office

NOW
ARRIVED
10mg Tablet

Return Ticket



- Effective control of symptoms.
- Resocialization and improved social performance.
- Low incidence of E.P.S.

once daily
Orap^{*}
 pimoziide

to help the schizophrenic patient
 regain his place in society.

PRESCRIBING INFORMATION Presentation White, scored, uncoated tablets marked "Janssen" on one side and 0/2 on the other, each contains 2 mg pimoziide. Pale green, scored, uncoated tablets marked "Janssen" on one side and 0/4 on the other, each contains 4 mg pimoziide. White, scored, uncoated tablets marked "Janssen" on one side and 0/10 on the other, each contains 10 mg pimoziide. Uses Orap* is an antipsychotic of the diphenyl butyl-piperidine series and is indicated for the treatment of acute or chronic schizophrenia. Hallucinations, delusions, thought disorders and emotional withdrawal respond well to lower doses of the drug. Higher doses may be needed for the control of acutely agitated, hyperactive or aggressive patients. Dosage and Administration Orap* is intended for oral administration to both adults and children. Patients may be maintained on a once daily dosage regime. As with all neuroleptics, it is important to determine the dose of Orap* according to the individual response of each patient. In adults: Dosage ranges between 2-20 mg daily. The usual initial dose is 4-10 mg, which may be varied according to response and tolerance to achieve an optimum maintenance dosage. In the acutely agitated patient the initial dose is 20 mg. Gradual reduction to the lowest effective maintenance dose may be attempted once control of symptoms is achieved. In children: In children over 12 years of age dosage should normally be 1-3 mg daily. Clinical experience in young children is limited and, therefore, Orap* should be used at the physician's discretion in children under 12 years of age. Contra-indications, warnings, etc. Contra-indications: Although no teratological changes have been observed in experimental animals, the drug should not be administered to pregnant women. Warnings: Endogenous depression, pre-existing Parkinson's disease and epilepsy may be aggravated. Overdosage: There is no specific antidote to an overdose of pimoziide. Cases should be treated symptomatically. A suicide attempt with 100 mg pimoziide produced only slight tremor and another with 200 mg showed no specific side-effects and needed no treatment. Side-effects: Extra-pyramidal effects may occur at higher dosage levels. Occasional skin rashes have been reported. Glycosuria has been reported following Orap* administration, but it has not been established whether this effect was drug related. Pharmaceutical precautions Nil. Legal category POM. Package quantities Orap* tablets each containing 2 mg pimoziide are supplied in packs of 100, 500 and 2,500. Orap* tablets each containing 4 mg pimoziide are supplied in a pack of 250. Orap* tablets each containing 10 mg pimoziide are supplied in a pack of 100. Further information Nil. Product licence numbers Orap* 2 mg 0242/5010, Orap* 4 mg 0242/0038, Orap* 10 mg 0242/0069. Basic N.H.S. Cost 10p/97p/day (4 mg x 250 pack) depending on dosage (2 mg-20 mg). (Correct at time of printing)

Further information is available and will gladly be supplied on request

Psychiatric Information Service. Janssen Pharmaceutical Ltd, Janssen House, Chapel Street, Marlow, Bucks. SL7 1ET

Psychological Med. 11, 1 <https://doi.org/10.1017/S0033291700053216> Published online by Cambridge University Press

Orap* is a trademark

CANADA

Alberta, Canada's fourth largest province, is experiencing unique growth based upon energy resources, complemented by a commitment to the future and an enhancement of the quality of life for its citizens. In medicine and health care, this commitment is evident in investment in facilities and services, emphasis on medical research and in support to universities.

Alberta Hospital, Edmonton is an active treatment psychiatric hospital comprised of acute admissions, geriatric, rehabilitation and forensic treatment services. Current vacancies exist in the Admission and Forensic services.

Admissions Service psychiatrists, under the direction of Dr. Flor-Henry, provide

direct patient care to newly-admitted patients (135 beds). Ten psychiatrists provide complete services to approximately 15 patients each.

Forensic Service psychiatrists, under the direction of Dr. Dry, work out of a new \$21 million hospital unit (150 beds) with extensive in-patient/out-patient treatment programs. Psychiatrists provide consultation services to parole and probation services to the courts and to various penal institutions. Individual working preferences will be met wherever possible.

Both services conduct clinical and research analysis in diverse areas of psychiatry including neuropsychological investigation and quantitative EEG analysis.

Forensic and Clinical Psychiatrists

work as leaders of inter-disciplinary teams, interacting with professional social workers, psychologists, occupational therapists and nurses.

Applicants must hold F.R.C.P.(C), M.R.C. (Psych) or equivalent.

Alberta has a vibrant economy and a high standard of living. It has the lowest provincial income tax rate in Canada and there is no sales tax or V.A.T.

Methods of remuneration are available to suit individual preferences:

Sessional Appointment — income based on hours worked, normally in the range of \$75,000 to \$100,000+ (CDN) per annum.

Contract Appointment — income based on monthly salary plus benefits, normally in the range of \$58,000 — \$66,000 (CDN) per annum.

Locums are also available to provide opportunity to work at Alberta Hospital, Edmonton to assist in arriving at a decision on permanent employment.

For further information please contact:

Dr. David R. Cornish
Medical Director
Alberta Hospital, Edmonton
Box 307, EDMONTON, Alberta
Canada T5J 2J7

The logo for the province of Alberta, featuring the word "Alberta" in a stylized, bold, sans-serif font. The letter 'A' is particularly large and prominent, with a thick stroke. The rest of the word follows in a similar style, with a slight curve at the end of the 'a'.

NOTES FOR CONTRIBUTORS

PAPERS Papers for publication should be addressed to the Editor, Professor Michael Shepherd, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF. Contributors should send at least three copies of the text, tables, and figures. Copies other than the first may be xeroxed. The S.I. system should be adopted for text and figures. A short synopsis of about 50 words should be provided at the beginning of each article. Foreign quotations and phrases should be followed by a translation. Submission of a paper will be held to imply that it contains original work that has not been previously published and that it is not being submitted for publication elsewhere.

In addition to longer articles, the Editor is prepared to accept preliminary communications of between 1500 and 2000 words.

Manuscripts must be typewritten on one side of the paper in double-spacing with wide margins. The following information must be given on a single separate sheet: (1) title and short title for running head (not more than 100 characters); (2) authors' names, and (3) department in which work was done. Footnotes on the same sheet should list: (i) the authors' present addresses if different from departments in which work was done; (ii) name and address of the author to whom correspondence should be addressed; (iii) receipt of grants. Authors who would like a reprint address to be printed should include this on their manuscript.

REFERENCES (1) In the text these should follow the Harvard system – that is, name followed by date: Brown (1970). If there are more than two authors the first author's name followed by *et al.* should be used, even the first time that the reference appears. (2) The list of references should be typed in alphabetical order on a separate sheet and should appear as follows: Brown, J., Williams, E. & Wright, H. (1970). Treatment of heroin addiction. *Psychological Medicine* 1, 134–136. Journal titles should be given in full.

Books should be cited as follows: Brown, J. (1970). *Psychiatric Research*. Smith: Glasgow.

ILLUSTRATIONS Only essential figures and tables should be included. *Photographs* Unmounted photographs on glossy paper should be provided. Magnification scales, if necessary, should be lettered on these. Where possible, prints should be trimmed to column width (i.e. 70 mm). *Diagrams* These will usually be reduced to 70 mm wide. Lettering should be in either Letraset or stencil, and care should be taken that lettering and symbols are of comparable size. Illustrations should not be inserted in the text, they should be marked on the back with figure numbers, title of paper, and name of author. All photographs, graphs, and diagrams should be referred to as figures and should be numbered consecutively in the text in Arabic numerals. The legends for illustrations should be typed on a separate sheet. *Tables* Tables should be numbered consecutively in the text in Arabic numerals and each typed on a separate sheet.

PROOFS AND OFFPRINTS Page proofs will be sent to the senior author. Corrections other than printer's errors may be charged to the author. Fifty offprints of each paper are supplied free; additional offprints are available according to a scale of charges if they are ordered when the proof is returned.

Psychological Medicine

Volume 11 Number 1 February 1981

CONTENTS

EDITORIALS

The epidemiology of life stress	page 1
The clinical significance of dysprosody	9
MACDONALD, M. Insanity and the realities of history in early modern England	11
BLAKEMORE, C. The future of psychiatry in science and society	27
JANOTA, I. Dementia, deep white matter damage and hypertension: 'Binswanger's disease'	39
CHADWICK, O., RUTTER, M., BROWN, G., SHAFFER, D. AND TRAUB, M. A prospective study of children with head injuries: II. Cognitive sequelae	49
BROWN, G., CHADWICK, O., SHAFFER, D., RUTTER, M. AND TRAUB, M. A prospective study of children with head injuries: III. Psychiatric sequelae	63
BERG, I., BUTLER, A., FAIRBAIRN, I. AND MCGUIRE, R. The parents of school phobic adolescents – a preliminary investigation of family life variables	79
LAZARUS, J. H., JOHN, R., BENNIE, E. H., CHALMERS, R. J. AND CROCKETT, G. Lithium therapy and thyroid function: a long-term study	85
GRUZELIER, J., CONNOLLY, J., EVES, F., HIRSCH, S., ZAKI, S., WELLER, M. AND YORKSTON, N. Effects of propranolol and phenothiazines on electrodermal orienting and habituation in schizophrenia	93
REID, A. H., NAYLOR, G. J. AND KAY, D. S. G. A double-blind, placebo controlled, crossover trial of carbamazepine in overactive, severely mentally handicapped patients	109
WING, L. Asperger's syndrome: a clinical account	115
BEUMONT, P. J. V., ABRAHAM, S. F. AND SIMSON, K. G. The psychosexual histories of adolescent girls and young women with anorexia nervosa	131
DARBY, P. L., GARFINKEL, P. E., VALE, J. M., KIRWAN, P. J. AND BROWN, G. M. Anorexia nervosa and 'Turner syndrome': cause or coincidence?	141
PEARLSON, G. D., FLOURNOY, L. H., SIMONSON, M. AND SLAVNEY, P. R. Body image in obese adults	147
WATKINS, G., TARNOPOLSKY, A. AND JENKINS, L. M. Aircraft noise and mental health: II. Use of medicines and health care services	155
HAWTON, K., BANCROFT, J., CATALAN, J., KINGSTON, B., STEDEFORD, A. AND WELCH, N. Domiciliary and out-patient treatment of self-poisoning patients by medical and non-medical staff	169
DUNN, G. The role of linear models in psychiatric epidemiology	179
STURT, E., BEBBINGTON, P., HURRY, J. AND TENNANT, C. The Present State Examination used by interviewers from a Survey Agency: report from the MRC Camberwell Community Survey	185
BRIEF COMMUNICATION	
Lithium and the changing incidence of mania R. L. SYMONDS AND P. WILLIAMS	193
BOOK REVIEWS	197

© Cambridge University Press 1981

CAMBRIDGE UNIVERSITY PRESS

The Pitt Building, Trumpington Street, Cambridge CB2 1RP
32 East 57th Street, New York, N.Y. 10022

Printed in Great Britain at the University Press, Cambridge